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PathologyThe mitochondrial H+-ATP synthase is a bottleneck component in the provision of metabolic energy by ox-
idative phosphorylation. The expression of its catalytic subunit (β-F1-ATPase) is stringently controlled at
post-transcriptional levels during oncogenesis, the cell cycle and in development. Here we show that miR-
127-5p targets the 3′UTR of β-F1-ATPase mRNA (β-mRNA) signiﬁcantly reducing its translational efﬁciency
without affecting β-mRNA abundance. Despite the reduced expression of β-F1-ATPase in most human carci-
nomas, we observed no expression of miR-127-5p in different human cancer cell lines, minimizing the poten-
tial role of miR-127-5p as a regulator of the bioenergetic activity of mitochondria in cancer. In contrast, miR-
127-5p is highly over-expressed in the human fetal liver. Consistent with previous ﬁndings in the rat, the ex-
pression of β-F1-ATPase in the human liver also seems to be controlled at post-transcriptional levels during
development, what might suggest a role for miR-127-5p in controlling β-mRNA translation and thus in deﬁn-
ing the bioenergetic activity of human liver mitochondria. Moreover, immunolocalization techniques and
subcellular fractionation experiments using different antibodies against β-F1-ATPase reveal that the ectopic
expression of β-F1-ATPase at the cell surface of the hepatocytes and HepG2 cells is negligible or stands
for scrutiny.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial activity provides the energy required for adapta-
tion to distinct environmental and physiological conditions of the or-
ganism. The mitochondrial H+-ATP synthase is the engine used for
ATP production by oxidative phosphorylation [1]. Previous studies
in yeast and mammalian tissues have shown that the expression of
the catalytic subunit of the H+-ATP synthase (β-F1-ATPase), which
is encoded in the nuclear genome, is mainly regulated by post-
transcriptional mechanisms that affect mRNA localization, stability
and translation [2–6]. In particular, during development of rat liver
[2,7], in brown adipose tissue [8] and in rat [4] and human [9] carci-
nomas the expression of β-F1-ATPase is regulated at the level of
translation. Mechanistically, both during development and in onco-
genesis β-F1-ATPase mRNA (β-mRNA) translation is masked byα and γ of the mitochondrial
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l rights reserved.speciﬁc factors that hinder ribosome recruitment onto the mRNA
[2,4,10,11]. In this regard, an important cis-acting element required
for β-mRNA translation is the 3′UTR of the transcript [2–6]. The 3′
UTR of β-mRNA acts as a translational enhancer both in vitro
[2,9,12] and in vivo [13], and is essential for the localization [5,6]
and efﬁcient translation of the transcript [2,9].
Post-transcriptional control of the expression of speciﬁc mRNAs
can be explained by the binding of regulatory proteins and/or miRNAs
to cis-acting elements of the mRNA. Recently, Ras-GAP SH3 binding
protein 1 (G3BP1) has been shown to interact with the 3′UTR of β-
mRNA to inhibit the initiation step of translation [11] contributing
in this way to the observed down-regulation of β-F1-ATPase expres-
sion in cancer. On the other hand, miRNAs are important post-
transcriptional regulators of gene expression [14]. miRNAs are short,
approximately 22-nucleotides long RNAs, that are transcribed as a
long primary transcript that folds into a hairpin structure. After nucle-
ar processing, the ~70 nucleotide precursor miRNA (pre-miRNA) is
exported to the cytoplasm and processed by Dicer into miRNA du-
plexes. One strand of the duplex represents the mature miRNA that
has to be incorporated into a miRNA-induced silencing complex
(RISC) to exert its biological function [14]. miRNAs regulate various
biological processes including developmental timing, cell fate deter-
mination, apoptosis and metabolism [15–17]. Changes in the expres-
sion of miRNAs are associated with human pathology including
cancer [14,18–21]. Animal miRNAs regulate gene expression by
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protein synthesis or inducing the degradation of the targeted mRNA
[22]. However, it has also been reported that some miRNAs can induce
translation of the target mRNA [23–25].
Due to the relevant implication of β-F1-ATPase in cell biology and
in human pathology [10,26] the aim of this study was to identify miR-
NAs that might be involved in post-transcriptional control of β-F1-
ATPase expression. For this purpose we generated stable cell lines
expressing GFP fused to the 3′UTR of human β-mRNA and searched
for potential miRNA that can modify the ﬂuorescence intensity of
the cells. We show that β-mRNA is speciﬁcally targeted and transla-
tionally silenced by miR-127-5p. We report that miR-127-5p is highly
expressed in human fetal liver and show that β-F1-ATPase expression
is post-transcriptionally regulated during human liver development.
We suggest that miR-127-5p might play a relevant role in controlling
the bioenergetic phenotype of the hepatocyte during human develop-
ment. Moreover, we have estimated that the content of β-F1-ATPase
at the plasma membrane of human and rat hepatocytes and HepG2
cells is insigniﬁcant as assessed by conventional immunological tech-
niques with validated antibodies.
2. Material and methods
2.1. Plasmids and cloning strategies
The plasmids expressing a hybrid GFP fused in frame with the
mitochondrial targeting sequence of β-F1-ATPase (pβ) [27] containing
either the 3′UTR of human β-mRNA (pβGFP-3′βh, pIW22) or α-F1-
ATPase mRNA (α-mRNA) (pβGFP-3′αh, pIW23) were cloned as
described [9]. The plasmid pβ-GFP-3′βMUT (pIW29) contains four
point mutations in the 3′UTR seed sequence of the hsa-miR-127-5p
binding site of β-mRNA. To introduce the mutations, two overlap-
ping PCR products containing the desired mutations were ampliﬁed
using oligos F-preβ-EGFP-KpnI: 5′-GCGGGTACCCGAATCCAGTCTC-
3′/R-3′hBmut-PCR1a: 5′-CACAGAAAAATAAGGGTCTTTGGGTTAGG-3′ and
F-3′β-h-EcoRI: 5′-GCGGAATTCGGGGTCTTTGTCCTCTGTA-3′ / F-3′hBmut-
PCR1b: 5′-CCTAACCCAAAGACCCTTATTTTTCTGTG-3′. The PCR products
were mixed 1:1, incubated for 5 min at 94 °C and 30min at 37 °C to
allow annealing of complementary tails. To form one full length mutated
PCR fragment, 1.75 mM dNTPs and 1 U/μl of Klenow DNA polymerase
were added and incubated for 30min at 37 °C. The product from this
reaction was used as a template for a second PCR reaction using the
outer primers F-3′β-h-EcoRI: 5′-GCGGAATTCGGGGTCTTTGTCCTCTGTA-3′
and R-3′β-h-XhoI: 5′-GCGCTCGAGTTTTTTTTTTTTTGAGGGGTGTA-3′. The
ampliﬁed PCR fragment was puriﬁed, digested with EcoRI and XhoI and
cloned into the pβGFP-3′Δ plasmid [9].
2.2. Cell cultures, generation of GFP expressing cells and transfection of
plasmids and miRNAs
The human BT549 breast and HepG2 liver cancer cell lines were
grown in RPMI and DMEM respectively, supplemented with 10% FBS,
400 μMnon-essential amino acids, 1 mM glutamine, 100 UI/ml penicil-
lin and 0.1 mg/ml streptomycine. Cells were transfected with plasmids
pβGFP-3′αh or pβGFP-3′βh using Lipofectamine and Plus reagent
(Invitrogen). After 24 h of transfection cells were split 1:10 and 1:20
into 10 cm plates and grown in the appropriate medium containing
0.3 mg/ml geneticin (G418, GIBCO). After 1–2 weeks isolated colonies
began to appear and the drug-resistant GFP-ﬂuorescent clones were
isolated with cloning cylinders and sub-cloned into 96-well plates.
The clones were expanded and the purity of the cell population ana-
lyzed byﬂow cytometry.miRNAswere transfected at the time of plating
using siPORT NeoFx reagent (Ambion/Applied Biosystems). The medi-
um was changed at 24 h post-transfection and the cells were analyzed
at 48 h post-transfection. miRNAs were used at a ﬁnal concentration
30 nM. The pre- and anti-miRNAs used in this study were purchasedfrom Ambion/Applied Biosystems and were PM11164 (pre-miRNA
hsa-miR-423-5p), PM11414 (pre miRNA hsa-miR-101), PM13001
(pre-miRNA hsa-miR-127-5p), PM11646 (pre-miRNA hsa-miR-581),
PM10492 (pre-miRNA hsa-miR-200b), PM11753 (pre-miRNA hsa-
miR-186), PM10632 (pre-miRNA hsa-miR-103), AM11164 (anti-
miRNA hsa-miR-423-5p), AM11646 (anti-miRNA hsa-miR-581),
AM10492 (anti-miRNA hsa-miR-200b), AM11753 (anti-miRNA hsa-
miR-186), AM10632 (anti-miRNA hsa-miR-103), AM13001 (anti-
miRNA hsa-miR-127-5p) and AM17110 (miRNA negative control #1).
Co-transfection of miR-127-5p and the plasmids pβ-GFP-3′βMUT or
pβ-GFP-3′β were performed in a 1:1 molar ratio using Lipofectamine
and Plus reagent (Invitrogen). In all cases the cell culture was
incubated with the cationic-lipid-DNA complexes for 2 h at 37 °C.
2.3. Flow cytometry
After 48 h of transfection cellular pellets were resuspended in
200–400 μl FACS solution (1% FBS, 0.1% NaN3 and 1×PBS) and analyzed
by ﬂow cytometry. The ﬂuorescence intensity of at least 10,000 events
was determined in a FACScan cytometer (Becton–Dickinson) using
CellQuest (Becton–Dickinson) acquisition software. The results were
analyzed with the program FlowJo (TreeStar).
2.4. Screening of potential miRNAs by ﬂuorescence reporter assays
Over-expression and silencing assays of the selected miRNAs were
performed in BT549 clones stably expressing a mitochondrial local-
ized GFP fused to the 3′UTR of β-F1-ATPase mRNA (BT549:pβGFP-
3′β) using the indicated miRNAs precursors (pre-miRNA), anti-
miRNAs and miRNA negative control #1. As an additional control of
the screening experiments BT549 clones stably expressing a mito-
chondrial localized GFP fused to the 3′UTR of α-F1-ATPase mRNA
(BT549:pβGFP-3′α) were studied in parallel. The assays were carried
out in 96-well plates with a black border and a clear ﬂat bottom
(Corning). After 48 h of transfection the cells were stained for
10 min at 37 °C with 5 μg/ml of Hoescht (Sigma) diluted in cell cul-
ture medium without phenol red. The ﬂuorescence intensity of
Hoescht (excitation: 340–10 nm, emission: 470–10 nm) and of GFP
(excitation: 485 nm, emission: 510–10 nm) was determined using a
FLUOstar Omega Microplate Reader (BMG Labtech). The ﬂuorescence
intensity of GFP was normalized by the number of cells as determined
by Hoechst ﬂuorescence intensity and quantiﬁed relative to the cells
transfected with a non-relevant miRNA (control).
2.5. Cloning, expression and puriﬁcation of γ-F1-ATPase and antibody
production
The cDNA (BC000931) encoding human γ-F1-ATPase (AAH35198)
was ampliﬁed by PCR using the LGC-Promochem MGC-5380 clone
and primers 5′-cgcgagctcatgttctctcgcgcg-3′ and 5′-atagtttagcggccg-
catccagagctgctgc-3′ which add SacI and NotI restriction sites, respec-
tively. The resulting product was puriﬁed and ﬁrst cloned into pGEM-
Teasy vector (Promega) and after into pQE-Trisystem [28]. The result-
ing plasmid, pQE-γF1, that encodes γ-F1-ATPase with C-terminal
6×His and streptavidin tags, was used to transform Escherichia coli
BL-21 cells. Protein expression was induced by addition of 1 mM
IPTG. After overnight induction, the cells were collected and the
expressed protein puriﬁed using Ni-NTA superﬂow resin (Qiagen)
[28]. To produce monoclonal antibodies against human γ-F1-
ATPase, we proceeded as recently described [28]. In brief, BALB/c
mice were immunized with various doses of the puriﬁed protein
(20 μg) and the hybridomas produced by fusing spleen cells with
the SP2 myelomas. Supernatants of the hybridomas were screened
by indirect ELISA on γ-F1-ATPase-coated polystyrene plates. Bound
antibodies were detected using horseradish-peroxidase-labeled goat
anti-mouse antibodies (1:1000 DAKO). The positive colonies were
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ﬁed with Montage antibody puriﬁcation kit (Millipore) and used at a
1:1000 dilution.
2.6. Quantiﬁcation of miRNA and mRNA
RNA was extracted from cell cultures using TRIzol Reagent (Invi-
trogen). Human fetal (20–44 weeks, #636540 from Clontech and
A601605 and A604419 from BioChain) and adult (51–64 year-old
men, #636531 from Clontech and B510061 and B510092 from Bio-
Chain) total liver RNA were purchased. The expression level of ma-
ture miRNAs was determined using TaqMan MicroRNA Assay from
Applied Biosystems, which includes a unique set of RT-PCR primers
and a speciﬁc TaqMan probe. RNA was reverse transcribed using the
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems).
The TaqMan MicroRNA Assays used in this study were RNU48
(#001006, Applied Biosystems), U6 snRNA (#001973, Applied Biosys-
tems) and hsa-miR-127-5p (#002229, Applied Biosystems). The qPCR
reaction was performed as indicated by the supplier using 2X Univer-
sal Master Mix without UNG (Applied Biosystems) and an ABI PRISM
7900 SDS thermocycler. Expression of miR-127-5p was determined
according to the ΔΔCt method using RNU48 (cell lines) or U6
(human samples) as internal controls, respectively. Quantiﬁcation of
β-mRNA, γ-F1-ATPase and succinate dehydrogenase subunit B
(SDH-B) mRNAs and 18S rRNA expression in human liver samples
by RT-PCR was performed as described [9,11].
2.7. Protein extraction and Western blotting
For protein extraction, cellular pellets were resuspended in lysis
buffer (25 mM Hepes, 2.5 mM EDTA, 1% Triton X-100, 1 mM PMSF
and 5 μg/ml leupeptin) supplemented with complete protease inhib-
itor cocktail EDTA-free (Roche). Cell lysates were clariﬁed by centrifu-
gation at 10,000×g for 7 min. Adult human liver samples were
obtained from the Banco de Tejidos y Tumores, IDIBAPS, Hospital
Clinic, Barcelona, Spain, coded for anonymity [29]. The Institutional
Review Board approved the project. Fetal human liver lysates were
purchased from ProSci Incorporated (#XBL-10409), Abcam
(ab29890) and BioChain (A605254). Protein concentrations were de-
termined with the Bradford reagent (Bio-Rad Protein Assay). Protein
extracts were fractionated on SDS-PAGE and transferred onto PVDF
membranes for immunoblot analysis. The primary monoclonal anti-
bodies used were: anti-Hsp60 (Stressgene SPA-807, 1:5000), anti-
GFP (Clontech, 1:10,000), anti-β-actin (Sigma, 1:100,000), anti-γ-
F1-ATPase (1:1000), anti-E-cadherin (BD Pharmigen, 1:1000) and
anti-SDH-B (Molecular Probes, 1:500), anti-β-F1-ATPase (Ab1) (Mo-
lecular Probes, 1:1000) and the polyclonal rabbit anti-β-F1-ATPase
(Ab2) (1:15,000) [29] and (Ab3) [30]. Peroxidase-conjugated anti-
mouse or anti-rabbit IgGs (Nordic Immunonology, 1:5000) were
used as secondary antibodies. The blots were developed using the
ECL reagent (Invitrogen).
2.8. Immunohistochemistry
Parafﬁn-embedded human liver 5 μm tissue sections were stained
using a diaminobenzidine-based method using the Envision-Plus-
horseradish peroxide system (DAKO) as detailed [29]. The dilution
of the anti-β-F1-ATPase (Ab2) used was 1:3000. Nuclei were counter-
stained with hematoxylin.
2.9. Electron microscopy
Small pieces (~1 mm3) of rat liver samples were ﬁxed by immer-
sion in freshly prepared 4% paraformaldehyde in 0.1 M Sörensen
phosphate buffer, pH 7.2 and supplemented with 6% sucrose, for 2 h
at 4 °C. Samples were rinsed in buffer and the free-aldehyde groupswere quenched with 50 mM ammonium chloride in PBS for 60 min
at 4 °C. Afterwards, the samples were rinsed in PBS, dehydrated in ac-
etone and ﬁnally processed for embedding in Lowicryl K4M (Poly-
sciences Europe, Eppelheim, Germany) according to manufacturer's
instructions. Gold interferential color ultrathin sections were collect-
ed in collodion/carbon-coated nickel grids. For the immunocyto-
chemical localization of β-F1-ATPase, the grids were incubated with
a 1:50 dilution of anti-β-F1-ATPase (Ab3) [30]. After three washes
with PBS, grids were incubated for 45 min with Protein A-gold com-
plex (10 nm). Fixation was carried out with 1% glutaraldehyde in
PBS. Counterstaining was performed with 2% uranyl acetate (7 min)
and 1% lead citrate (45 s). The grids were observed in a Jeol 1010 elec-
tron microscope under 80 kV accelerating voltage.
2.10. Immunoﬂuorescence
For double-immunoﬂuorescence microscopy HepG2 cells were
grown on coverslips and ﬁxed with 2% paraformaldehyde in PBS for
30 min. Cellular permeabilization was achieved by incubation with
0.1% Triton X-100 for 10 min. Coverslips were ﬁrst incubated in 1%
FCS in PBS for 10 min and washed before incubation with the primary
monoclonal anti-β-catenin (BD Pharmingen, 1:100) and the poly-
clonal anti-β-F1-ATPase (Ab2) antibodies. After, coverslips were in-
cubated for 1 h in the dark with goat-anti rabbit IgGs conjugated to
Alexa 594 and goat anti-mouse IgGs conjugated to Alexa 488. Cellular
staining was analyzed in a confocal microscope Biorad Radiance 2000
Zeiss Axiovert S100TV.
2.11. Puriﬁcation of mitochondria and plasma membranes
Rat liver homogenates were prepared in a solution containing
0.25 M sucrose, 1 mMEGTA and10 mMTris–HCl pH 7.4 and centrifuged
at 800 g for 10 min to remove nuclei and unbroken cells. The resulting
post-nuclear supernatants (H) were fractionated on 35 ml sucrose
density gradients [24–54% (w/v)]. The gradients were centrifuged at
145,000 g for 70 min at 4 °C. Fractions were collected from the bottom
of the tube and the localization of mitochondria (Mi) performed by
western blotting using antibodies against β-F1-ATPase and Hsp60.
Liver post-nuclear supernatants (H) were centrifuged ﬁrst at 8500 g
for 10 min and the resulting supernatants were further centrifuged at
180,000 g for 1 h. The resulting microsomal pellet was homogenized
in 20 ml of 57% sucrose and placed on the bottom of the centrifuge
tube. Thirtyml of 34% sucrosewas added on top of themicrosomal sam-
ple. The discontinuous gradient was centrifuged at 54,000 g for 16 h at
4 °C. Fractionswere collected from the bottom of the tube and the local-
ization of the plasma membrane (PM) fraction performed by western
blotting using antibodies against E-cadherin (BD Pharmingen, 1:1000).
2.12. Statistical analysis
Statistical analyses were performed using a two-tailed Student's
t-test. The results shown are means±SEM. A pb0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Potential miRNAs targeting the 3′UTR of human β-mRNA
In order to identify potential miRNAs that could bind the 3′UTR
of human β-mRNA we performed a bioinformatic study using the
miRNA target prediction software TargetScan5.1 (http://www.
targetscan.org/). The TargetScan prediction algorithm is based on
few binding rules [31–33]. In brief, the most important requirement
seems to be a contiguous and perfect Watson–Crick base pairing of
the 5′-miRNAs “seed” region. Matching of the mRNA to the miRNA
seed can be divided into 8mer-, 7mer- and 6mer-sites. An A residue
Fig. 1. Tools for the identiﬁcation of miRNAs targeting the 3′UTR of human β-mRNA. (A) Schematic illustration of the 3′UTR of human β-mRNA and of the miRNAs predicted to
bind the 3′UTR with higher afﬁnity (TargetScan). Binding sites and types of the miRNAs selected are indicated in color code. The hypoxia regulated miR-103 (light green) was also
included in the study for the putative relevance that hypoxia might play in regulating β-F1-ATPase expression. Generation and analysis of the BT549:pβGFP-3′β (B) and BT549:
pβGFP-3′α (C) cell lines used to screen the activity of miRNAs. Graphs in B and C illustrate the GFP ﬂuorescence of BT549 clones that express mitochondria-targeted GFP fused
to the 3′UTR of human β-mRNA (clone β2, orange and β10, blue) or to the 3′UTR of α-mRNA (clone α2, magenta and α4, blue), respectively. The percentage of GFP expressing
cells is indicated. The basal cellular ﬂuorescence of the parental wild type (WT) BT549 cells is shown in red trace. Representative immunoﬂuorescence examples of the targeting
of GFP (green) to MitotrackerRed stained mitochondria (red) in BT549:pβGFP-3′β (B) and BT549:pβGFP-3′α (C) cells.
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improves miRNA activity [33]. In addition, miRNAs that are conserved
among different species are preferentially selected. Following these
binding rules and with the purpose of covering the entire length of
the 3′UTR of β-mRNA we selected miR-101, miR-127-5p, miR-186,
miR-200b, miR-423-5p and miR-581 as the strongest candidates from
the in silico results (Fig. 1A). miR-103 was also included in the
study because of the putative relevance that hypoxia [34] might have
in regulating β-F1-ATPase expression, even though miR-103 does not
ﬁt to the above mentioned rules.
3.2. miR-127-5p is a potential regulator of β-F1-ATPase expression
For screening purposes, and in order to analyze the inﬂuence of
miRNAs on the expression of β-F1-ATPase in breast cancer cells, we
generated BT549 cell lines that stably express a mitochondrial tar-
geted GFP reporter bearing the 3′UTR of β-mRNA (Fig. 1B). The pre-
sequence of β-F1-ATPase (pβ) was fused in frame upstream of the
GFP coding region to localize the reporter protein into mitochondria
[27] because this cis-acting element of β-mRNA is also required for
the appropriate subcellular localization of the mRNA [6]. To assess
the speciﬁcity of the action of the selected miRNAs on the 3′UTR of
β-mRNA we also developed BT549 cell lines stably expressing the
same reporter but containing the 3′UTR of α-F1-ATPase mRNA
(α-mRNA) (Fig. 1C) which is a counterpart subunit of β-F1-ATPase in
the mitochondrial H+-ATP synthase [1]. After generation of the stable
cell lines both the pβGFP-3′α and pβGFP-3′β expressing cells were
analyzed by ﬂow cytometry to analyze the purity of the clones aswell as their GFP ﬂuorescence intensity. The analysis showed that
the selected pβGFP-3′β (β2 and β10 in Fig. 1B) and pβGFP-3′α
(α2 and α4 in Fig. 1C) clones exhibited a well-deﬁned and single peak
of high-intensity GFP ﬂuorescence (> 103 a.u.), indicating a very high
degree of purity (> 98%). The red traces in Fig. 1B and C show the back-
ground of the ﬂuorescence signal of wild type cells (100–101 a.u.).
Therefore, shifts in the ﬂuorescence intensity of the generated clones
can be taken as indicative of interfering GFP expression by the effect
of the transfected miRNA precursor molecules (pre-miRNAs), which
are designed to directly enter the miRNA processing pathway and
mimic endogenous miRNAs in the cells. Moreover, all the clones
targeted GFP to mitochondria as revealed by the co-localization of GFP
ﬂuorescence with Mitotracker Red by confocal microscopy (Fig. 1B
and C).
In order to identify which of the selected miRNAs might be relevant
in controlling β-F1-ATPase expression we ﬁrst carried out miRNA over-
expression experiments using miRNA precursors (pre-miRNA) in the
GFP-tagged cells. The relative activity of the miRNAs targeting the 3′
UTR of β-mRNA was assessed by determining the relative GFP ﬂuores-
cence intensity of pβGFP-3′β clones when compared to that of pβGFP-
3′α clones (Fig. 2A). The study revealed that from all the miRNAs
analyzed only miR-127-5p triggered a signiﬁcant decrease in GFP ﬂuo-
rescence in both pβGFP-3′β clones (β2 and β10 in Fig. 2A) when
compared to pβGFP-3′α clones (α4 in Fig. 2A) and cells transfected
with a non-relevant miRNA (control in Fig. 2A). Western blot analysis
of pβGFP-3′β2 cells conﬁrmed a reduced expression of the GFP reporter
when cells were treated with miR-127-5p (Fig. 2B). Notably, silencing
experiments using the corresponding anti-miRNAs, including anti-
Fig. 2. Fluorescence reporter assays identify miR-127-5p as a potential regulator of β-F1-ATPase expression. A, The GFP ﬂuorescence intensity of two BT549 cell clones (β2 in
yellow and β10 in green) expressing pβGFP-3′β was determined after 48 h of transfection with the indicated miRNAs precursors using a ﬂuorescence luminometer. Data were
normalized relative to the number of cells as determined by Hoescht ﬂuorescence intensity and quantiﬁed relative to the mean GFP ﬂuorescence of control cells transfected
with a non-relevant miRNA (control). The ﬂuorescence intensity of BT549 cells expressing pβGFP-3′α (α4 in black) was also analyzed as an additional control of the screening.
The results shown are the means±SEM of three independent experiments. *, pb0.0001 when compared to pβGFP-3′α by Student's t-test. B,Western blot analysis of GFP expres-
sion in total cell lysates of BT549:pβGFP-3′β2 cells non-transfected (NTF) or transfected with pre-miR-127-5p (miR-127-5p) or a scramble miRNA (control). The GFP/β-actin ratio is
indicated. C, Fluorescence reporter assays using anti-miRNAs. The GFP ﬂuorescence intensity of two BT549 cell clones (β2 in yellow and β10 in green) expressing pβGFP-3′β was
determined after 48 h of transfection. Data were normalized as indicated in A. The ﬂuorescence intensity of BT549 cells expressing pβGFP-3′α (α4 in black) was also analyzed as an
additional control of the screening. The results shown are the means±SEM of three independent experiments. D, Western blot analysis of GFP expression in total cell lysates of
BT549:pβGFP-3′β2 cells non-transfected (NTF) or transfected with anti-miR-127-5p or a scramble miRNA (control). The GFP/β-actin ratio is indicated.
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ﬂuorescence intensity (Fig. 2C) and GFP expression (Fig. 2D) of pβGFP-
3′β clones when compared to controls.
3.3. β-mRNA is targeted and silenced by miR-127-5p
Next, we questioned about the activity of miR-127-5p on the
expression of the endogenous β-F1-ATPase. Transfection of miR-
127-5p precursors in parental BT549 cells provoked a signiﬁcant
decrease in the expression of β-F1-ATPase protein (Fig. 3A, histogram
to the left). In this situation, the cellular content of β-mRNA was not
affected when compared to control cells that were transfected with
a non relevant miRNA (Fig. 3A, histogram to the right). Consistent
with the above mentioned ﬁndings (Fig. 2C and D) the transfection
of BT549 cells with anti-miR-127-5p had no effect on β-F1-ATPase
expression (Fig. 3B), suggesting that BT549 breast cancer cells do
not express signiﬁcant levels of miR-127-5p. The determination of
miR127-5p expression in BT549 and other cancer cell lines conﬁrmed
the lack of expression of this miRNA in these cells (see Fig. 5A), raising
the question of what is the physiological context where miR127-5p
might be of relevance in controlling the expression of human β-F1-
ATPase. Anyway, the negative effect of miR-127-5p on β-F1-ATPase ex-
pression was further underlined by the observation that the expression
of β-F1-ATPase was restored to that of control cells when miR-127-5p
expression was silenced by co-transfection with anti-miR-127-5p
(Fig. 3B).
To verify that the down-regulation of β-F1-ATPase expression is
due to the targeting of miR-127-5p to its presumed binding site on
the 3′UTR of β-mRNA we generated a mutated version of thepβGFP-3′β expression plasmid (pβGFP-3′βMUT) that contains four
point mutations on the miR-127-5p binding region (Fig. 4A). Prelim-
inary experiments indicated that the ﬂuorescence intensity of pβGFP-
3′βMUT expressing cells was not signiﬁcantly affected by the co-
expression of miR-127-5p (1.00 versus 0.96 arbitrary units in the
absence or presence of miR-127-5p, respectively). Analysis of GFP
ﬂuorescence in BT549 cells co-transfected with the miR-127-5p
precursor and pβGFP-3′β or pβGFP-3′βMUT plasmids revealed that
whereas miR-127-5p signiﬁcantly inhibited GFP ﬂuorescence derived
from the pβGFP-3′β plasmid the expression of GFP derived from the
mutated plasmid was not affected (Fig. 4A). These ﬁndings were further
conﬁrmed bywestern blot analysis (Fig. 4B), that illustrated a very sharp
reduction of GFP expression derived from the pβGFP-3′β plasmid
whereas GFP expression was not affected from the pβGFP-3′βMUT
expressing cells. It should be noted that over-expression of miR-127-
5p promoted in both pβGFP-3′β and pβGFP-3′βMUT expressing cells a
signiﬁcant reduction of the endogenous β-F1-ATPase (Fig. 4B). Taken
together, these results illustrate that miR-127-5p targets the 3′UTR
of human β-mRNA and interferes with translation of the transcript.
It appears that western blots are more sensitive than ﬂuorescence
analysis to illustrate the activity of a particular miRNA (compare
differences in GFP expression between Fig. 4B and A). Since this
situation raised the possibility that other of the miRNAs studied
in this work (Fig. 2A) could have some effect on β-F1-ATPase
expression, presumably with less activity than miR-127-5p, we
also veriﬁed the activity of the miRNAs by western blotting
(Fig. 4C). The results obtained conﬁrmed the data of the ﬂuorescence
study (Fig. 2A), i.e., only miR-127-5p has relevant activity as regulator
of the expression of β-F1-ATPase (Fig. 4C).
Fig. 3. miR-127-5p inhibits the translation of β-mRNA. A, Western blot analysis of the expression of β-F1-ATPase in total cell lysates (histogram to the right) and RT-qPCR
quantiﬁcation of β-mRNA (histogram to the left) of BT549 cells transfected with miR-127-5p precursor (miR-127-5p, open bars) or a scramble miRNA (control, closed bars).
Lanes 1 and 2 correspond to two different experiments of the same experimental condition. The results shown are the mean±SEM of three independent experiments. The
quantiﬁcation of β-F1-ATPase expression is indicated using β-actin as reference protein. *, pb0.001 when compared to control by Student's t-test. B, Analysis of β-F1-ATPase
expression in BT549 cells transfected with miR-127-5p precursor (open bar), anti-miR-127-5p (gray bar), both miR-127-5p precursor+anti-miR-127-5p (hatched bar) or a
negative control miRNA (control, closed bar). The quantiﬁcation of β-F1-ATPase expression is indicated using Hsp60 as reference protein. The results shown are the means±
SEM of four independent experiments. *, pb0.05 when compared to control by Student's t-test.
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To identify in which physiological context miR-127-5p could affect
β-F1-ATPase expression we ﬁrst analyzed by RT-qPCR its expression in
several human cancer cell lines. The results obtained revealed that
breast (BT549 and T47D), colon (HCT116), lung (Hop62), HeLa and
Jurkat cancer cells do not express signiﬁcant levels of miR-127-5p
(Fig. 5A), most likely indicating that miR-127-5p does not play a
role in silencing β-mRNA translation in these carcinomas. In contrast,
human fetal liver samples expressed highly signiﬁcant levels of miR-
127-5p when compared to adult livers (Fig. 5A), suggesting that it
might play a role in controlling β-F1-ATPase expression in the human
liver during development. Interestingly, the expression of proteins
involved in energy metabolism, such as subunits β-F1-ATPase and
γ-F1-ATPase of the mitochondrial H+-ATP synthase and of subunit B
of succinate dehydrogenase (SDH-B) is barely detectable in fetal liver
extracts but show a remarkable increase in their expression in the
adult liver (Fig. 5B). In contrast, it should be noted that the expression
of the structural mitochondrial protein Hsp60 did not show signiﬁcant
differences between fetal and adult liver extracts (Fig. 5B). Therefore,
the β-F1-ATPase/Hsp60 ratio increased signiﬁcantly during develop-
ment of the human liver (Fig. 5B), in agreement with previous results
in rat liver that illustrated the rapid postnatal biogenesis and functional
differentiation of mammalian mitochondria [7,35–37]. Consistent with
the relevance of translational control for the biosynthesis of β-F1-
ATPase observed in lower mammals [36], we noted that liver mRNA
levels for both the β and γ subunits of the H+-ATP synthase as well as
of SDH-B showed no relevant changes during development (Fig. 5C),
i.e., the mRNAs are represented at the time of development when the
amount of the proteins is very limited. This was not the situation for
the liver content of Hsp60 where both mRNA (Fig. 5C) and protein
(Fig. 5B) levels correlated.3.5. β-F1-ATPase is not expressed at the plasma membrane of
the hepatocytes
It has been reported that β-F1-ATPase is a high-density lipopro-
tein (HDL) receptor for apolipoprotein A-I localized on the plasma
membrane of rat and human hepatocytes and HepG2 cells [38]. To
ﬁnd out the fraction that plasma membrane β-F1-ATPase might rep-
resent from the total cellular content of the protein we have studied
the expression and localization of β-F1-ATPase in rat and human
liver as well as in HepG2 cells using different experimental tech-
niques and antibodies (Ab1, Ab2 and Ab3) (Fig. 6). Immunohisto-
chemistry of parafﬁn-embedded human liver sections using a
polyclonal antibody against β-F1-ATPase (Ab2) [29] revealed no im-
munoreactive material on the plasma membrane of the hepatocytes
whereas a strong labeling of cytoplasmic organelles was observed
(Fig. 6A). High-resolution immunoelectron microscopy of rat liver
thin sections, using a different antibody (Ab3) [30], showed a strong
gold decoration of mitochondria of the hepatocytes in the absence
of plasma membrane recognition of any immunoreactive material
(arrows in Fig. 6B). Double-immunoﬂuorescence microscopy of
non-permeabilized HepG2 cells using an antibody against β-catenin,
a plasma membrane protein (green, Fig. 6C) and anti-β-F1-ATPase
(Ab2) (red, Fig. 6C) showed the almost complete absence of β-F1-
ATPase on the plasma membrane. The only red signals appeared dec-
orating the mitochondria of the few cells (b10%) that are inevitably
permeabilized as a result of the ﬁxation procedure (arrow in
Fig. 6C). Similar ﬁndings were obtained using a commercially avail-
able antibody against β-F1-ATPase (Ab1) (data not shown). As
expected, both Ab2 (Fig. 6D) and Ab1 (data not shown) speciﬁcally
recognized mitochondria in permeabilized HepG2 cells. Altogether,
we show that various cellular ﬁxation procedures and localization
techniques using different antibodies against β-F1-ATPase only
Fig. 4. miR-127-5p speciﬁcally targets the 3′UTR of human β-mRNA. A, Schematic illustration of the four point mutations (in red, asterisks) introduced in the 3′UTR of β-mRNA to
generate the pβ-GFP-3βMUT plasmid (3βMUT). On top, the miR-127-5p (green) seed matching sequence on the 3′UTR of β-mRNA is indicated (highlighted in gray). The histogram
shows the ﬂuorescence intensity of BT549 cells co-transfected with miR-127-5p or a negative control miRNA (control) and reporter plasmids expressing GFP fused either to the 3′
UTR of β-mRNA (3′β) (open and closed bars) or to the mutant 3′UTR of β-mRNA (gray bar, 3′βMUT). The results shown are the mean±SEM of three independent experiments.
*, pb0.001 when compared to control by Student's t-test. B, Western blot analysis in total cell lysates of BT549 cells co-transfected with miR-127-5p precursor (lanes 1–4)
or a negative control miRNA (control, closed bar) (lanes 5 and 6) and the reporter plasmids expressing GFP fused to the wild type 3′β (open bar) (lanes 1 and 2) and control
(lanes 5 and 6) or mutant (3′βMUT, gray bar) (lanes 3 and 4) 3′UTR of β-mRNA. Two different experiments assayed in the same gel for each condition are shown. The lower histogram
shows β-F1-ATPase (β-F1) expression relative to that of β-actin. The results shown are the mean±SEM of four experiments. *, pb0.005 when compared to control by Student's t-test.
Note the lack of effect of miR-127-5p on GFP expression derived from the 3′βMUT and the silencing of the endogenous β-F1-ATPase. C, Western blot analysis of β-F1-ATPase
(β-F1) expression in BT549 cells transfected with the indicated miRNAs precursors or a scramble miRNA (control). The β-F1/β-actin ratio is indicated.
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marginal presence of β-F1-ATPase at the plasma membrane of mam-
malian liver cells.
Furthermore, rat liver homogenates were prepared and the mito-
chondria and plasma membrane fractions puriﬁed (Fig. 6E). Western
blotting of proteins from these fractions using speciﬁc antibodies
against mitochondria (Hsp60 and β-F1-ATPase) and plasma mem-
brane (E-cadherin) markers, conﬁrmed the enrichment of mitochon-
dria (compare H versus Mi in Fig. 6E) and plasma membranes
(compare H versus PM in Fig. 6E) in their respective fractions. Re-
markably, none of the three antibodies used against β-F1-ATPase rec-
ognized a band in the plasma membrane fractions (Fig. 6E). Similar
negative ﬁndings have been obtained using a monoclonal anti-β-F1-
ATPase (data not shown) developed recently [39]. These results also
support that there is no ectopic expression of β-F1-ATPase on thecell surface of liver cells or, alternatively, that the content of β-F1-
ATPase in the plasma membrane is negligible when considered the
total cell content of the protein. Therefore, and for the rest of this
work, we will not take into consideration the contribution that the
plasma membrane protein could have in this study.
4. Discussion
The control of β-F1-ATPase expression is essential for normal cell
function. In fact, down-regulation of its expression is linked to cancer
progression [10,29,40] or to the onset of a small group of devastating
rare diseases [26]. In the present study we have investigated the role
that miRNAs could play in controlling β-F1-ATPase expression in
humans and the likely physiological context where they might exert
their function. This is part of an ongoing project aimed at the
Fig. 5. miR-127-5p is expressed in fetal human liver. A, Quantiﬁcation of miR-127-5p expression by RT-qPCR in human cancer cell lines (BT549, T47D, HCT116, Hop62, Jurkat and
HeLa) and in fetal and adult human liver. miR-127-5p expression in the cell lines and during liver development was normalized to RNU48 and U6 RNA, respectively. The results
shown are the mean±SEM of three experiments. *, pb0.005 when compared to fetal by Student's t-test. B, Western blot analysis of the expression of the mitochondrial proteins
Hsp60, β-F1-ATPase (β-F1), γ-F1-ATPase (γ-F1) and subunit B of succinate dehydrogenase (SDH-B) in human fetal and adult liver extracts. The expression of β-actin was used as
reference of protein loading. Lanes 1 and 2 under the same heading correspond to two different fetal or adult liver extracts. The histogram summarizes the relative expression level
of each protein in adult liver extracts (open bars) relative to the level observed in fetal extracts (closed bars). The β-F1-ATPase/Hsp60 ratio is also shown. The results shown are the
mean±SEM of three different extracts.*, pb0.01 when compared to fetal by Student's t-test. C, RT-qPCR analysis of β-F1-ATPase mRNA, γ-F1-ATPase mRNA, SDH-B mRNA and
Hsp60 mRNA in fetal (closed bars) and adult (open bars) human liver samples. Data were normalized relative to 18S rRNA and are shown as fold change relative to the values
in fetal liver. The results shown are the mean±SEM of three different samples.
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regulation of β-F1-ATPase expression in human pathophysiology
[4,10,11]. Initially, we intended to characterize the mechanism of re-
pression of β-F1-ATPase expression in breast cancer [9]. Therefore, the
BT549 breast cancer cell line was selected for developing the GFP-3′β
and GFP-3′α clones because it is a cell line that shows an intermediate
expression level of β-F1-ATPase when compared to other breast cancer
cells of the NCI panel (T47D, MDA-N>BT5490=HS578T>MCF7, ADR-
RES, MDA-231, MDA-435). Of the sevenmiRNAs studied we found that
only miR-127-5p functionally interferes with β-F1-ATPase expression.
Moreover, it was further found that this miRNA is not expressed in
many cancer cells. This unexpected ﬁnding promoted the search for
other physiological contexts where miR-127-5p might play a role in
regulating the translation of β-mRNA and found its likely participation
in development of the liver. A recent report identiﬁed miR-101 as a
post-transcriptional regulator of β-F1-ATPase expression in HeLa cells
[41]. Our ﬂuorescence and western blot data in BT549 cells does not
support such a role for miR-101 perhaps due to differences in the cells
studied. In general, miRNAs silence gene expression by induction of
mRNA degradation or by inhibition of its translation [22,42–44]. We il-
lustrate that expression of miR-127-5p brings about a profound de-
crease in the steady state level of the endogenous β-F1-ATPase
without affecting β-mRNA levels. Moreover, we show that miR-127-
5p speciﬁcally targets the 3′UTR of the transcript. These results indicate
that the mechanism of action of miR-127-5p on β-F1-ATPase expres-
sion is exerted by repressing β-mRNA translation.
In the mouse miR-127 is expressed in embryos, placenta and post-
natal brain and muscle [45] as well as in fetal lung [46]. It is expressed
as a part of a cluster with miR-136, miR-431, miR-432, and miR-433
both in normal tissues and cultured ﬁbroblasts of mouse and humans
[45,47]. The expression of the cluster and speciﬁcally of miR-127 is
down-regulated in primary tumors and various cancer cell lines [47].
Moreover, the miR-127 promoter is embedded in a CpG island andremains methylated in most tissues except sperm [47]. Treatment of
cancer cells with chromatin-modifying drugs promoted the up-
regulation of miR-127 which targets the mRNA of the protooncogene
BCL6 to inhibit its expression [47]. Consistent with these ﬁndings,
miR-127 is over-expressed in diffuse large B-cell lymphomas [48]
and Epstein–Bar virus (EBV) positive Burkitt lymphomas [49], sup-
porting that miR-127 acts as a potential tumor suppressor by blocking
terminal differentiation of B-cells and hence favoring their prolifera-
tion [47–49]. A role for miR-127 has been suggested in the control of
cellular differentiation because it is preferentially expressed in the
mesenchymal rather than in the epithelial compartment of the lung
towards the end of fetal stages of development [46]. In fact, over-
expression of miR-127 in fetal lung cultures impedes normal lung dif-
ferentiation [46]. Consistent with these ﬁndings we report that miR-
127-5p is highly over-expressed in the fetal liver. Hence, we suggest
that miR-127-5p does not play a role in controlling β-F1-ATPase ex-
pression in oncogenesis and thus in promoting the down-regulation
of the protein that accompanies the bioenergetic switch during cellu-
lar transformation [10,40] but rather it represses the differentiation of
mitochondria during fetal liver development [35].
Cancer cells and embryonic tissues display large phenotypic simi-
larities regarding the molecular and functional activities of mitochon-
dria [37,50]. In fact, fetal hepatocytes and hepatocarcinomas are
highly glycolytic cells because both the number and the bioenergetic
activity of their mitochondria are very low [35,37,50]. Consistent with
the observations in lower mammals recent reports demonstrated that
the activity of oxidative phosphorylation complexes increases signif-
icantly in liver, brain, muscle and heart of humans after birth
[51,52]. The analogies also affect the mechanisms that control the ex-
pression of genes of the H+-ATP synthase because β-mRNA is accu-
mulated in a translation repressed state in fetal rat liver [2,7,36], in
rat hepatocarcinomas [4] and in human lung, colon and breast carci-
nomas [9]. Accumulation of β-mRNA in developing liver and in rat
Fig. 6. No evidence for the localization of β-F1-ATPase at the plasma membrane. A, Immunohistochemical characterization of the expression of β-F1-ATPase in human
liver sections using a polyclonal anti-β-F1-ATPase (Ab2) only reveals the mitochondrial localization of the protein. B, High-resolution immunoelectron microscopy of rat
liver ultrathin sections processed with a polyclonal anti-β-F1-ATPase (Ab3) reveals the speciﬁc labeling (10 nm gold, white stripes) of mitochondria (m) in the absence
of gold decoration of the plasma membrane (arrows) of the hepatocyte. C, Double immunoﬂuorescence microscopy of non-permeabilized HepG2 cells with anti-β-catenin (green) and
anti-β-F1-ATPase (Ab2) (red) reveals non-relevant immunolabeling of β-F1-ATPase on the plasma membrane. The only red signals observed (β-F1-ATPase) are conﬁned to cytoplasmic
organelles in few partially permeabilized cells as a result of the ﬁxation procedure (arrow). D, Double immunoﬂuorescence microscopy of permeabilized HepG2 cells reveals the almost
complete absence of β-catenin signal (green). The strong red signals of the β-F1-ATPase antibody (Ab2) are conﬁned to cytoplasmic organelles. E, Western blotting of rat liver postnuclear
supernatants (H), puriﬁed mitochondria (Mi) and plasma membrane (PM) proteins using three different antibodies against the β-subunit of the H+-ATP synthase (Ab1, Ab2 and Ab3).
Probing of the membranes with anti-hsp 60 and anti-E-cadherin, markers of mitochondria and plasma membrane, respectively, conﬁrmed the enrichment of mitochondria and plasma
membranes in their respective fractions. The blots show no immunoreactivity against β-F1-ATPase at the PM fraction.
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transcript [4,36]. The storage of masked β-mRNA in the fetal liver and
its rapid translational activation immediately after birth [2,7,36] is re-
quired to promote the functional differentiation of liver mitochondria
[35] allowing adaptation of mammals to the aerobic environment. In
agreement with these ﬁndings our study illustrates that subunits β
and γ of the H+-ATP synthase are hardly expressed in human fetal
liver boosting their expression in the adult liver. Paradoxically, and
consistent with ﬁndings in rat liver [36], we observed no differences
in steady state β-mRNA levels in the human liver during development
strongly suggesting that the low content of β-F1-ATPase in humans
also results from translation silencing of the corresponding mRNA.
Similar paradoxical ﬁndings were obtained for the counterpart γ-
F1-ATPase subunit. The mechanisms that control the translation of
β-mRNA are very complex [10] and, in addition to miR-127-5p, β-
F1-ATPase expression is also regulated by speciﬁc RNA-binding pro-
teins such as G3BP1 that also targets the 3′UTR of the transcript
[11]. In this scenario, we suggest that protein- and RNA-mediated
mechanisms that regulate the interaction of essential cis-acting ele-
ments of β-mRNAwith the translational machinery are of upmost im-
portance to unveil β-F1-ATPase expression in different physiological
contexts [10]. Importantly, the β-F1-ATPase/Hsp60 ratio, which illus-
trates the energetic competence of mitochondria [29], showed a sig-
niﬁcant increase after birth. This ﬁnding indicates that human fetal
liver mitochondria are deﬁcient in the molecular components of the
H+-ATP synthase and perhaps in mitochondrial functionality, resem-
bling very much the ﬁndings obtained in lower mammals [37,50].
Within this context, miR-127-5p might be of physiological relevanceto regulate the attenuation of β-mRNA translation during develop-
ment of the human fetal liver.
Remarkably, the promoter of humanmiR-127 gene can be activated
by estrogen related receptor gamma (ERRγ) and alpha (ERRα)
transcription factors [53]. Functional and biochemical studies have
shown that ERRα is involved in energy metabolism and mitochondrial
biogenesis [54]. Together with PGC-1α, ERRα is involved in the induc-
tion of the ATP5B gene that encodes β-F1-ATPase [55,56]. Thus, one
can speculate that during fetal stages of human liver development
ERRα simultaneously activates the transcription of β-F1-ATPase and
of miR-127-5p, the repressor of β-mRNA translation. This could pro-
mote the accumulation of masked β-mRNA in the fetal liver ensuring
a less functionality of the H+-ATP synthase to allow an active glycolysis
which is the main pathway of the proliferating hepatocyte [40]. It is
likely that the targeting of miR-127-5p to its presumed binding site in
the 3′UTR of β-mRNA is an assisted process exerted in cooperation
with the RNABPs that built the human β-RNP [11,21]. Post-
translational modiﬁcation of any of these proteins [21] by the cellular
signaling events that occur in mammals after birth [57] might induce
the release of miR-127-5p from β-mRNA to allow its effective transla-
tion and the functional differentiation of human liver mitochondria.
Within this context, miR-127-5p could function in human liver devel-
opment in a similar way to that of miR-378* in cancer, which has
been shown to be an important regulator of the bioenergetic switch ex-
perienced in breast cancer for adjusting the cell to a changingmetabolic
demand [58].
Taken together, our results indicate that translational control of
β-mRNA is also operative during human liver development. Since
847I.M. Willers et al. / Biochimica et Biophysica Acta 1817 (2012) 838–848miR-127-5p is highly expressed in the fetal human liver and targets the
3′UTR of β-mRNA repressing its translation we suggest that it offers a
potential candidate for controlling the expression of β-F1-ATPase
during development and therefore in regulating the bioenergetic
differentiation of human liver mitochondria.
5. Conclusion
miR-127-5p targets the 3′UTR of β-F1-ATPasemRNA (β-mRNA) and
inhibits its translation without affecting β-mRNA abundance. The
expression of β-F1-ATPase is controlled at the level of translation
during development of the human liver. Since miR-127-5p is highly
expressed in the fetal human liver we suggest that it might be involved
in deﬁning the bioenergetic activity of mitochondria in the hepatocyte
during development.
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